Cesca Therapeutics to Present at the 9th Annual Biotech Showcase
January 03 2017 - 6:00AM
Cesca Therapeutics Inc. (NASDAQ:KOOL), a market leader in automated
cellular processing and point-of-care autologous cell-based
therapeutics, today announced that it is scheduled to present at
the 9th Annual Biotech Showcase, being held on January 9-11, 2017
at the Hilton San Francisco Union Square in San Francisco, CA.
Dr. Xiaochun “Chris” Xu, Cesca’s Interim Chief
Executive Officer, will provide an update of the Company’s business
during the live presentation and will be available to participate
in one-on-one meetings with investors who are registered to attend
the conference.
Details for the presentation are as follows:
Date: Monday, January 9, 2017Time: 5:00PM
PSTLocation: Room 2 (Ballroom Level)
About Cesca Therapeutics Inc.Cesca Therapeutics
Inc. (www.cescatherapeutics.com) is engaged in the research,
development, and commercialization of cellular therapies and
delivery systems for use in regenerative medicine. The Company is a
leader in the development and manufacture of automated blood and
bone marrow processing systems that enable the separation,
processing and preservation of cell and tissue therapeutics.
These include:
- The SurgWerks™ System (in development) - a
proprietary system comprised of the SurgWerks Processing Platform,
including devices and analytics, and indication-specific SurgWerks
Procedure Kits for use in regenerative stem cell
therapy at the point-of-care for vascular and orthopedic
diseases.
- The CellWerks™ System (in development) - a
proprietary cell processing system with associated analytics for
intra-laboratory preparation of adult stem cells from bone marrow
or blood.
- The AutoXpress® System (AXP®) - a proprietary
automated device and companion sterile disposable for concentrating
hematopoietic stem cells from cord blood.
- The MarrowXpress™ System
(MXP™) - a derivative product of the AXP and its accompanying
sterile disposable for the isolation and concentration of
hematopoietic stem cells from bone marrow.
- The BioArchive® System - an automated
cryogenic device used by cord blood banks for the cryopreservation
and storage of cord blood stem cell concentrate for future
use.
- Manual bag sets for use in the processing and
cryogenic storage of cord blood.
Forward-Looking StatementThe
statements contained herein may include statements of future
expectations and other forward-looking statements that are based on
management’s current views and assumptions and involve known and
unknown risks and uncertainties that could cause actual results,
performance or events to differ materially from those expressed or
implied in such statements. A more complete description of risks
that could cause actual events to differ from the outcomes
predicted by Cesca Therapeutics' forward-looking statements is set
forth under the caption "Risk Factors" in Cesca Therapeutics annual
report on Form 10-K and other reports it files with the Securities
and Exchange Commission from time to time, and you should consider
each of those factors when evaluating the forward-looking
statements.
Company Contact: Cesca Therapeutics Inc.
ir@cescatherapeutics.com
Investor Contact: The Ruth Group
Lee Roth / Tram Bui
646-536-7012 / 7035
lroth@theruthgroup.com / tbui@theruthgroup.com
Cesca Therapeutics (NASDAQ:KOOL)
Historical Stock Chart
From Mar 2024 to Apr 2024
Cesca Therapeutics (NASDAQ:KOOL)
Historical Stock Chart
From Apr 2023 to Apr 2024